These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23083038)

  • 1. Comparative study on the level of B lymphocyte stimulator (BlyS) and frequency of lymphocytes between sero-negative and sero-positive rheumatoid arthritis patients.
    Geng Y; Zhang ZL
    Int J Rheum Dis; 2012 Oct; 15(5):478-85. PubMed ID: 23083038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders.
    La DT; Collins CE; Yang HT; Migone TS; Stohl W
    Ann Rheum Dis; 2008 Aug; 67(8):1132-8. PubMed ID: 17967830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse.
    Cambridge G; Stohl W; Leandro MJ; Migone TS; Hilbert DM; Edwards JC
    Arthritis Rheum; 2006 Mar; 54(3):723-32. PubMed ID: 16508933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
    Fabris M; Quartuccio L; Vital E; Pontarini E; Salvin S; Fabro C; Zabotti A; Benucci M; Manfredi M; Ravagnani V; Biasi D; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Bazzicchi L; Saracco M; Pellerito R; Cimmino M; Carraro V; Semeraro A; Schiavon F; Caporali R; Bortolotti R; Govoni M; Fogolari F; Tonutti E; Bombardieri S; Emery P; De Vita S
    Arthritis Rheum; 2013 Jan; 65(1):88-97. PubMed ID: 23001900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and effects of B-lymphocyte stimulator and its receptors in T cell-mediated autoimmune arthritis.
    Chang Y; Sun X; Jia X; Xu S; Wei F; Yang X; Wei W
    Int Immunopharmacol; 2015 Feb; 24(2):451-457. PubMed ID: 25598291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study on the diversity of clinical features between the sero-negative and sero-positive rheumatoid arthritis patients.
    Geng Y; Zhou W; Zhang ZL
    Rheumatol Int; 2012 Dec; 32(12):3897-901. PubMed ID: 22198665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of different T follicular helper subsets in rheumatoid arthritis].
    Chen XM; Li J; Zhang XY; Jin YB; Yu D; Sun XL; Wu LJ; He J; Li ZG
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):958-963. PubMed ID: 27987497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in synovial tissue infiltrates between anti-cyclic citrullinated peptide-positive rheumatoid arthritis and anti-cyclic citrullinated peptide-negative rheumatoid arthritis.
    van Oosterhout M; Bajema I; Levarht EW; Toes RE; Huizinga TW; van Laar JM
    Arthritis Rheum; 2008 Jan; 58(1):53-60. PubMed ID: 18163491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-22+ CD4+ T cells in patients with rheumatoid arthritis.
    Zhao L; Jiang Z; Jiang Y; Ma N; Zhang Y; Feng L; Wang K
    Int J Rheum Dis; 2013 Oct; 16(5):518-26. PubMed ID: 24164838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definition of follicular helper T cell and cytokines expression in synovial fluid of rheumatoid arthritis.
    Pan S; Xiao X; Li T; Wu S; Zhou J; Tan S; Cheng J; Tian Y; Zhang H; Zhang X
    Clin Rheumatol; 2024 Jan; 43(1):129-135. PubMed ID: 37792147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in the study of BLyS and APRIL on regulating T cell responses in rheumatoid arthritis].
    Chang Y; Wei W
    Yao Xue Xue Bao; 2013 Jul; 48(7):979-85. PubMed ID: 24133964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Tryptophan-related Metabolomic Profile in Rheumatoid Arthritis Synovial Fluid.
    Kang KY; Lee SH; Jung SM; Park SH; Jung BH; Ju JH
    J Rheumatol; 2015 Nov; 42(11):2003-11. PubMed ID: 26329338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synovial fluid levels of anti-cyclic citrullinated peptide antibodies and IgA rheumatoid factor in rheumatoid arthritis, psoriatic arthritis, and osteoarthritis.
    Caspi D; Anouk M; Golan I; Paran D; Kaufman I; Wigler I; Levartovsky D; Litinsky I; Elkayam O
    Arthritis Rheum; 2006 Feb; 55(1):53-6. PubMed ID: 16463412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [B lymphocyte stimulator (BLyS/BAFF) level in sera of patients with lupus].
    Mercado U; Díaz-Molina R
    Rev Med Inst Mex Seguro Soc; 2016; 54(3):334-7. PubMed ID: 27100979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma level of neopterin as a marker of disease activity in treated rheumatoid arthritis patients: association with gender, disease activity and anti-CCP antibody.
    Arshadi D; Nikbin B; Shakiba Y; Kiani A; Jamshidi AR; Boroushaki MT
    Int Immunopharmacol; 2013 Nov; 17(3):763-7. PubMed ID: 24055018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.
    Iwata S; Nakayamada S; Fukuyo S; Kubo S; Yunoue N; Wang SP; Yoshikawa M; Saito K; Tanaka Y
    Arthritis Rheumatol; 2015 Jan; 67(1):63-73. PubMed ID: 25303149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis.
    Greisen SR; Rasmussen TK; Stengaard-Pedersen K; Hetland ML; Hørslev-Petersen K; Hvid M; Deleuran B
    Scand J Rheumatol; 2014; 43(2):101-8. PubMed ID: 24182347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.
    Greiner A; Plischke H; Kellner H; Gruber R
    Ann N Y Acad Sci; 2005 Jun; 1050():295-303. PubMed ID: 16014545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher levels of matrix metalloproteinase-3 in patients with RA reflect disease activity and structural damage.
    Skacelova M; Hermanova Z; Horak P; Ahmed K; Langova K
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):296-302. PubMed ID: 28461705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset.
    Berglin E; Johansson T; Sundin U; Jidell E; Wadell G; Hallmans G; Rantapää-Dahlqvist S
    Ann Rheum Dis; 2006 Apr; 65(4):453-8. PubMed ID: 16176994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.